Search

The article focuses on the feasibility in the use of the inhibitor Panobinostat in patients with relapsed multiple myeloma (MM) alongside dexamethasone and bortezomib. It talks about the clinical trial for progression-free survival (PFS) in patients going through disease relapse. It tells about the need to improve the efficiency of the drugs Dexamethasone, Bortezomib and Thalidomide alongside the inhibitor.

A growing population of long-term survivors of myeloma is now accumulating the 'late effects' not only of myeloma itself, but also of several lines of treatment given throughout the course of the disease. It is thus important to recognise the cumulative burden of the disease and treatment-related toxicity in both the stable and active phases of myeloma, some of which is unlikely to be detected by routine monitoring. We summarise here the evidence for the key late effects in long-term survivors of myeloma, including physical and psychosocial consequences (in Parts 1 and 2 respectively), and recommend the use of late-effects screening protocols in detection and intervention. The early recognition of late effects and effective management strategies should lead to an improvement in the management of myeloma patients, although evidence in this area is currently limited and further research is warranted. [ABSTRACT FROM AUTHOR]

Supportive care plays an increasingly important role in the modern management of multiple myeloma. While modern treatments have significantly prolonged overall and progression free survival through improved disease control, the vast majority of patients remain incurable, and live with the burden of the disease itself and the cumulative side effects of treatments. Maintenance of quality of life presents challenges at all stages of the disease from diagnosis through the multiple phases of active treatment to the end of life. Written on behalf of the British Committee for Standards in Haematology (BCSH) and the UK Myeloma Forum (UKMF), these evidence based guidelines summarize the current national consensus for supportive and symptomatic care in multiple myeloma in the following areas; pain management, peripheral neuropathy, skeletal complications, infection, anaemia, haemostasis and thrombosis, sedation, fatigue, nausea, vomiting, anorexia, constipation, diarrhoea, mucositis, bisphosphonate-induced osteonecrosis of the jaw, complementary therapies, holistic needs assessment and end of life care. Although most aspects of supportive care can be supervised by haematology teams primarily responsible for patients with multiple myeloma, multidisciplinary collaboration involving specialists in palliative medicine, pain management, radiotherapy and surgical specialities is essential, and guidance is provided for appropriate interdisciplinary referral. These guidelines should be read in conjunction with the BCSH/UKMF Guidelines for the Diagnosis and Management of Multiple Myeloma 2011. [ABSTRACT FROM AUTHOR]

The article offers information on the guidelines for the diagnosis and management of multiple myeloma in 2011 as recommended by the U.S. Agency for Healthcare Research and Quality. The annual incidence of myeloma in Great Britain is approximately 60-70 per million. The overall prevalence is likely to be increasing given the recently published data demonstrating improved survival rates over the last decade. Investigation of a patient with suspected myeloma should include the screening tests.

The article presents a guideline to provide healthcare professionals with clear guidance for the effective clinical investigation of patients with newly detected M-proteins. It offers them the practical management of patients with monoclonal gammopathy of undetermined significance (MGUS). This article also discusses the background of MGUS and provides information on M-proteins.

The article presents information on a survey on the incidence of biphosphonates-associated jaw osteonecrosis in Great Britain. A postal survey of 648 healthcare professionals in the nation was conducted between Spring and Autumn in 2006, which included the details of their experience of treating myeloma using bisphosphonates during 2004 and 2005.